The clostridium genes are anaerobic gram-positive spore forming bacilli. There is about 50 recognized species in which 30 causes clinical disease. Clostridium are globally found soil, decaying vegetation, marine sediments and gastrointestinal tract of human, vertebrates and insects. Clostridium bacteria also be isolated from infected sites. They are prototype for toxins which are made by anaerobes. They have ability to cause botulism, colitis, gastroenteritis, soft-tissue infections, tetanus and neutropenic enterocolitis. The general treatment for the clostridium disease is antibiotics like metronidazole, vancomycin and fidaxomicin. The metronidazole and vancomycin are most used for treatment of clostridium infections as an initial treatment.
The United State clostridium diagnostic market is witnessing tremendous growth during forecast period 2022 - 2028. The growing incidences of clostridium infection is gaining the attention of many key player for the diagnosis and treatment of clostridium bacteria. The dynamic factors like increasing prevalence of clostridium diseases in country is propelling the market growth. The initiatives taken by governments such as awareness programs to educate individuals is also refuelling the market growth. Rise in presymptomatic testing of blood is also driving the market growth of United States clostridium diagnostic market. However, high of cost of diagnosis is hindering the market growth.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the clostridium diagnostic market. In addition, complete analysis of changes on clostridium diagnostic expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The clostridium diagnostic market is also experienced negative impact of COVID-19 pandemic. The rising in adoption of different strategies to reduce the widespread of the bacteria and viruses. During the pandemic situation witnessed very low cases of clostridium infection with respect to previous years non pandemics.
The clostridium diagnostic market is categorised by technology, product and end users.
The United States clostridium diagnostic market is comprised of technologies like immunoassay and molecular diagnostic. In which immunoassay is likely to dominate the market in 2020. The immunoassays is the most reliable and sensitive technology currently available for diagnosis and monitoring of different diseases. It works by use of antibodies for detection of small biological substance in blood and body fluids. The immunoassays follows principle that particular antigen binds to specific freshly introduced antibodies, thereby activating an immune response. It is highly selective bioanalytical method for detection of presence or concentration of analyte like small molecules or macromolecules.
The United States clostridium diagnostic market is bifurcated by the products like clostridium difficile, clostridium perfringens, clostridium botulinum, clostridium tetani, clostridium sordellii. In which clostridium tetani is also contributing in market growth. The clostridium tetani is common soil bacterium and causative agent of tetanus. Vegetative cells of C. tetani is usually rod-shaped and 2.5µm long, however it become enlarged and looks alike tennis racket or drumstick shape at the time of forming spores. The bacteria enters by deep flesh wound and cause production of toxins and causes tetanospasmin. The clostridium tetani is treated by metronidazole or penicillin by intravenous routes and treatment lasts for seven to ten days.
The United States clostridium diagnostic market is comprised of end users like hospitals, government diagnostic laboratory and independent laboratories. In which independent laboratories are also contributing in the market growth of United States clostridium diagnostic market. Independent laboratory is a person or group which specifies authentication or testing for identification, characterisation and confirmation of specifications. The independent laboratories are providing the unbiased result of diagnosis. Increase in quality assurance evaluations is also propelling the market growth. The results of independent laboratories are easy to replicate and also have precise control of extraneous and independent variables.
The major market players of clostridium diagnostic market are like Abbott Laboratories, Beckman Coulter Inc., Becton, Dickinson & Company, Biomerieux Sa, Chrono-Log Corporation, Corgenix, Diazyme Laboratories, F. Hoffmann-La Roche Ag, Fujirebio Us Inc., Hologic Inc., Qiagen Gmbh, Siemens Healthineers, Sysmex Corporation and Thermo Fisher Scientific Inc. among the others.
The study comprised of clostridium diagnostic market. In which the market is segmented into the technology, product and end users. The study also comprised dominating segment of the market. The technology segment is dominated by immunoassay. Likewise, product segment is leaded by clostridium difficile and end user segment is dominated by hospitals. The study also comprised of the impact of COVID-19 on the market and concludes that The COVID-19 has almost affected every market is healthcare industries positively or negatively. The clostridium diagnostic market is also experienced negative impact of COVID-19 pandemic. The rising in adoption of different strategies to reduce the widespread of the bacteria and viruses. During the pandemic situation witnessed very low cases of clostridium infection with respect to previous years non pandemics. The study also summarizes the leading players operating in the market.
Why to buy this report :